Semaglutide vs tirzepatide: cost and efficacy compared
One GLP-1 agonist, one dual agonist. The head-to-head efficacy gap, the pricing gap, and a cost-per-result framework to decide which fits your goals and budget.
The efficacy comparison
Both are incretin-based injectables, but they differ mechanistically: semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 agonist. The direct head-to-head, SURMOUNT-5, found tirzepatide reached 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks. Semaglutide's own STEP 1 figure was ~14.9%. So on average efficacy, tirzepatide leads — but semaglutide remains highly effective and better-studied over long horizons.
The cost comparison
Compounded semaglutide is frequently priced lower than compounded tirzepatide. In our July 2026 datasets, flat-rate compounded semaglutide runs about $145/month versus roughly $186/month for flat-rate compounded tirzepatide. On the brand side, both are expensive without insurance (Wegovy/Ozempic ~$1,300–$1,400; Zepbound/Mounjaro ~$1,000–$1,350).
Cost per result
Dividing annual cost by trial-average efficacy is a rough but useful lens. Flat-rate compounded semaglutide (~$1,740/yr ÷ 14.9%) is about $117 per percentage point; flat-rate compounded tirzepatide (~$2,232/yr ÷ 20.2%) is about $110. They're remarkably close on cost-efficiency — tirzepatide buys more absolute loss, semaglutide costs less per month. This is an illustrative pricing comparison, not a clinical claim about individuals.
Who should choose which
Prioritizing maximum average weight loss and comfortable with a higher monthly cost? Tirzepatide has the efficacy edge. Cost-sensitive, want the longer real-world track record, or tolerate semaglutide better? Semaglutide is the value play. Either way, suitability, tolerability, and dose are clinical decisions. Our comparison table and cost calculator can frame the numbers; a licensed prescriber frames the medicine.
Tolerability, availability, and the practical tie-breakers
Efficacy and price get the headlines, but the decision between semaglutide and tirzepatide often turns on quieter factors. Tolerability is broadly similar — both are dominated by GI side effects that cluster during titration — though individual response varies enough that some people tolerate one markedly better than the other. Because there's no way to predict this in advance, the practical implication is that a program allowing a switch without penalty has real option value.
Track record is another tie-breaker. Semaglutide has been in widespread use longer, with a deeper real-world safety and outcomes literature including the SELECT cardiovascular trial. Tirzepatide is newer and produces larger average weight loss, but with a correspondingly shorter observational history. For a patient who weights the reassurance of accumulated evidence, that tilts toward semaglutide; for one who prioritizes maximum average loss, toward tirzepatide.
Availability and pricing consistency round it out. In the compounded market we track, semaglutide programs are slightly more numerous and often a bit cheaper, which can matter in states with thinner telehealth availability. The honest bottom line is that neither drug is universally "better" — they occupy different points on the efficacy-cost-evidence frontier, and the right pick depends on which axis you weight most. What we can say cleanly is the pricing: flat-rate compounded semaglutide is the lower monthly commitment, which is why cost-sensitive readers frequently start there. Suitability, dose, and switching are clinical decisions for a prescriber, and this comparison is about framing the trade-offs, not making that call for you.
Frequently asked questions
Is tirzepatide or semaglutide more effective for weight loss?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss (20.2% vs 13.7% over 72 weeks). Semaglutide remains highly effective (~14.9% in STEP 1) with a longer real-world track record. The best choice depends on individual priorities and clinical suitability.
Is compounded semaglutide cheaper than tirzepatide?
Generally yes. In our July 2026 data, flat-rate compounded semaglutide runs about $145/month versus roughly $186/month for flat-rate compounded tirzepatide. Both brand products are expensive without insurance.
Which has better cost-per-result, semaglutide or tirzepatide?
They're close. Flat-rate compounded semaglutide is about $117 per percentage point of trial-average loss; tirzepatide about $110. Tirzepatide buys more absolute weight loss; semaglutide costs less per month. This is an illustrative pricing comparison, not a clinical claim.
Can I switch between semaglutide and tirzepatide?
Switching is a clinical decision made with a prescriber based on response, tolerability, and goals. Both require their own titration schedules. Do not switch or adjust dosing without medical guidance.
References
- Aronne LJ, et al. Tirzepatide vs semaglutide (SURMOUNT-5). N Engl J Med. 2025.
- Wilding JPH, et al. STEP 1. N Engl J Med. 2021.
- Semaglutide Price Guide and Tirzepatide Price Guide July 2026 datasets.
- FDA labeling for Wegovy, Ozempic, Zepbound, and Mounjaro.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.